Original ArticleLestaurtinib (cas 111358-88-4) is Cytotoxic to Oxaliplatin-resistant Transitional Cell Carcinoma Cell Line T24 In Vitro

Add time:08/30/2019    Source:sciencedirect.com

ObjectivePatients with bladder cancer have responded poorly to oxaliplatin therapy in clinical trials. Blockade of receptor tyrosine kinases is considered a good strategy in cancer therapy. Our previous studies have demonstrated the crucial roles of brain-derived neurotrophic factor and its receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma (TCC). The aim of this study was to examine the cytotoxic effects of lestaurtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines.

We also recommend Trading Suppliers and Manufacturers of Lestaurtinib (cas 111358-88-4). Pls Click Website Link as below: cas 111358-88-4 suppliers

Prev:Lestaurtinib (cas 111358-88-4)
Next:Lestaurtinib (cas 111358-88-4) (CEP-701) modulates the effects of early life hypoxic seizures on cognitive and emotional behaviors in immature rats)